L-Selectin/CD62L Antibody Pair [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-79372
Recombinant Monoclonal Antibody
Key Product Details
Assay Type
Sandwich ELISA
Assay Range
9.375-600 pg/ml (example only; lot dependent)
Sensitivity
9.375 pg/ml (example only; lot dependent)
Reactivity
Human
Product Specifications
Description
Solid Phase sandwich ELISA for the quantitative determination of Human L-Selectin/CD62L.
Sample Volume Required
100 ul
Conjugate
HRP
Scientific Data Images for L-Selectin/CD62L Antibody Pair [HRP]
Sandwich ELISA: L-Selectin/CD62L Antibody Pair [HRP] [NBP2-79372] - This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
Kit Contents for L-Selectin/CD62L Antibody Pair [HRP]
- Rabbit Monoclonal Capture Antibody: (Catalog # NBP2-89997)
- Rabbit Monoclonal Detection Antibody (HRP-conjugated): (Catalog # NBP2-89996)
- Standard
Preparation and Storage
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Storage of components varies. See protocol for specific instructions.
Background: L-Selectin/CD62L
L-selectin expressed on leukocytes binds to ligands expressed by endothelial cells where it plays a role in lymphocyte homing to secondary lymphoid organs (2-5). L-selectin specifically recognizes and binds to sulfated sialyl-Lewis epitopes of O-linked glycans (2-4). Ligands for L-selectin include glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), CD34, mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1), and P-selectin glycoprotein ligand-1 (PSGL-1) (2,4). Elevated levels of selectin ligands on tumor cells are associated with cancer progression and metastasis (3). High levels of L-selectin and soluble L-selectin (sL-selectin) has been implicated in a number of pathologies from viral infection and allergies, to sepsis and multiple sclerosis (2,4,5). For example, L-selectin has been shown to play a role in human immunodeficiency virus (HIV) infection. HIV envelope glycans, such as gp120, binds to L-selectin/CD62L on CD4+ T cells, facilitating viral adhesion (2,5). A disintegrin and metalloproteinase (ADAM)17 is the primary enzyme responsible for L-selectin shedding in leukocytes, which is triggered in response to inflammatory signals (1,2,5). AMAD17 inhibitors block L-selectin shedding and reduce viral release (2,5). Given their role in cancer and other diseases, selectins and their ligands are potential targets for therapeutic intervention (3,5). For instance, murine models have shown that anti-L-selectin antibodies can delay onset of graft versus host disease (5).
References
1. Ivetic A. (2018). A head-to-tail view of L-selectin and its impact on neutrophil behaviour. Cell and Tissue Research, 371(3), 437-453. https://doi.org/10.1007/s00441-017-2774-x
2. Ivetic, A., Hoskins Green, H. L., & Hart, S. J. (2019). L-selectin: a major regulator of leukocyte adhesion, migration and signaling. Frontiers in Immunology, 10, 1068. https://doi.org/10.3389/fimmu.2019.01068
3. Borsig L. (2018). Selectins in cancer immunity. Glycobiology, 28(9), 648-655. https://doi.org/10.1093/glycob/cwx105
4. Kneuer, C., Ehrhardt, C., Radomski, M. W., & Bakowsky, U. (2006). Selectins-potential pharmacological targets?. Drug Discovery Today, 11(21-22), 1034-1040. https://doi.org/10.1016/j.drudis.2006.09.004
5. Segura, J., He, B., Ireland, J., Zou, Z., Shen, T., Roth, G., & Sun, P. D. (2021). The role of L-Selectin in HIV infection. Frontiers in Microbiology, 12, 725741. https://doi.org/10.3389/fmicb.2021.725741
Alternate Names
CD62L, hLHRc, LAM1, LECAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR, SELL, TQ1
Gene Symbol
SELL
Additional L-Selectin/CD62L Products
Product Documents for L-Selectin/CD62L Antibody Pair [HRP]
Product Specific Notices for L-Selectin/CD62L Antibody Pair [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Antibody Pairs are guaranteed for 6 months from date of receipt.
Loading...
Loading...
Loading...
Loading...